MYC–IgH — oncology-focused definition
MYC–IgH refers to the fusion of the MYC oncogene (chromosome 8q24) with the immunoglobulin heavy chain (IgH) locus (chromosome 14q32) due to the t(8;14) translocation.
Oncology relevance:
- Mechanism: IgH enhancer drives overexpression of MYC, promoting uncontrolled proliferation and reduced apoptosis.
- Disease association:
- Burkitt lymphoma (classic hallmark)
- Sometimes seen in other high-grade B-cell lymphomas
Clinical significance (for oncology pharmacists):
- Diagnostic marker: Confirms Burkitt lymphoma when seen on FISH or karyotyping.
- Prognostic marker: Indicates highly aggressive disease, requiring intensive multi-agent chemotherapy.
- Therapeutic relevance: While MYC itself is undruggable, the presence of MYC–IgH guides treatment intensity and monitoring.
Key takeaway:
The MYC–IgH fusion is a driver of aggressive B-cell malignancy, central to diagnosis, prognosis, and treatment planning in Burkitt lymphoma.
Links